Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

Core Insights - Eli Lilly and Company announced preclinical data for agents targeting SMARCA2 and multiple KRAS mutations to be presented at the AACR Annual Meeting from April 25-30, 2025 [1] Group 1: Presentation Details - Lilly, in collaboration with Foghorn Therapeutics, will present preclinical data for LY4050784, a selective SMARCA2 inhibitor, in combination with chemotherapy, pembrolizumab, and KRAS inhibitors [2] - Preclinical data for LY4066434, a pan-KRAS inhibitor, will also be presented, demonstrating robust anti-tumor activity in KRAS-mutant models [2] - Specific presentation details include: - Title: LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitors - Abstract Number: 3779 - Session Date & Time: April 28, 2:30-4:30 p.m. CST - Presenter: Nathan Brooks [2] - Title: LY4066434, an oral small molecule pan-KRAS inhibitor, demonstrates robust anti-tumor activity in KRAS-mutant models, including in the CNS - Abstract Number: 4375 - Session Date & Time: April 29, 9 a.m.-12 p.m. CST - Presenter: Hong Gao [2] Group 2: Company Overview - Eli Lilly is focused on turning scientific discoveries into healing solutions, with a history of nearly 150 years in pioneering life-changing medicines [3] - The company aims to address significant health challenges, including diabetes care, obesity, Alzheimer's disease, immune system disorders, and difficult-to-treat cancers [3] - Lilly emphasizes the importance of innovative clinical trials that reflect global diversity and aims to ensure accessibility and affordability of its medicines [3]